239 - Immunodiagnostic assay for detecting urinary nuclear matrix protein 52 in patients with bladder cancer

Date 28 September 2012
Event ESMO Congress 2012
Session Publication Only
Topics Urothelial Cancers
Translational Research
Basic Principles in the Management and Treatment (of cancer)
Presenter Hoda Abdel Latif
Authors H.A. Abdel Latif1, H. El-Hadaad2
  • 1Histology And Cell Biology, Mansoura University, Faculty of Medicine, Mansoura/EG
  • 2Clinical Oncology, Mansoura University Hospital School of Medicine, 35511 - Mansoura/EG



To report the rapid and simple detection of a nuclear matrix protein (NMP) in the urine of patients with bladder cancer using dot-enzyme-linked immunosorbent assay (ELISA).

Patients and methods

Urine sample from 120 patients with bladder cancer and 60 controls were evaluated using western blot and specific immunoglobulin G antibody to identify the urinary NMP marker using the developed dot-ELISA. The initial response and follow up of 82 patients treated by irradiation were followed using the assay.


The NMP marker was identified in the urine of patients with cancer bladder at 52 KDa (NMP-52) by Western blot. The dot-ELISA detected the urinary NMP-52 marker in 85% of patients with squamous cell carcinoma and 92% with transitional cell carcinoma. The positive and negative predictive values (95% and 91% respectively) and efficiency (92%) of the dot-ELISA were high. NMP-52 tumor marker detection was correlated with the response to radiotherapy.


Detection of the urinary NMP-52 marker using dot-ELISA would be helpful in rapid diagnosis and follow up patients with bladder cancer.


All authors have declared no conflicts of interest.